title: Antidepressant response and intolerance to SSRI is not influenced by G-protein beta3 subunit gene C825T polymorphism in Japanese major depressive patients.
abstract: The G-protein beta3 subunit (GNB3) gene is a key modulator of signal transduction and is a major candidate for SSRIs response. The aim of the present study is to test a possible effect of the C825T polymorphism on the antidepressant response and intolerance to selective serotonin reuptake inhibitors (SSRIs) in 146 Japanese samples with major depression treated with paroxetine or fluvoxamine for 6 weeks. The severity of depression symptom was assessed using the 21-item Hamilton Rating Scale for Depression (HAM-D) and adverse drug reactions were evaluated bi-weekly. No association with SSRIs treatment response was observed in 107 completers also including HAM-D baseline scores, SSRI type or/and 5-HTTLPR variants in the model as covariates. Furthermore, no significant association could be observed with intolerance to SSRIs in the whole subjects. The result suggests that C825T variants of GNB3 cannot play a major role as a predictor of treatment response as well as intolerance to SSRIs in Japanese patients with major depression.
authors.affiliation: Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan. masaki.kato@unibo.it
authors.forename: Masaki
authors.initials: M
authors.lastname: Kato
authors.forename: Masataka
authors.initials: M
authors.lastname: Wakeno
authors.forename: Gaku
authors.initials: G
authors.lastname: Okugawa
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Fukuda
authors.forename: Yoshiteru
authors.initials: Y
authors.lastname: Takekita
authors.forename: Yuka
authors.initials: Y
authors.lastname: Hosoi
authors.forename: Junichi
authors.initials: J
authors.lastname: Azuma
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Kinoshita
authors.forename: Alessandro
authors.initials: A
authors.lastname: Serretti
mesh_terms: D000328:Adult; D000928:Antidepressive Agents / Q000009:adverse effects* / Q000097:blood / Q000627:therapeutic use*; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000235:genetics / Q000523:psychology; D005260:Female; D016666:Fluvoxamine / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use; D005838:Genotype; D020962:Heterotrimeric GTP-Binding Proteins / Q000235:genetics*; D006801:Humans; D007564:Japan; D008297:Male; D008875:Middle Aged; D017374:Paroxetine / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use; D011110:Polymorphism, Genetic / Q000235:genetics; D011569:Psychiatric Status Rating Scales; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects* / Q000097:blood / Q000627:therapeutic use*
chemical_list: D000928:Antidepressive Agents; D016666:Fluvoxamine; D020962:Heterotrimeric GTP-Binding Proteins; D017374:Paroxetine; D017367:Selective Serotonin Reuptake Inhibitors; C454420:G-protein beta3 subunit